Clinical trials: Body Weight Control
Morbid Obesity
Six-month Study to Compare the Effects of Volume- and Pressure-Guided Adjustments on Weight Loss and Satiety
The purpose of this protocol is to determine how band fill volumes that are based on intraband pressure readings can influence the comfortability of the band and to compare weight loss with this methodology to weight loss with…
- Trial name
- NCT00960843
- Testing
- Intraband pressure recording system, Conventional Adjustment
- Where
- 2 sites in Australia, Czechia
- Volunteers
- 51 people
- Sponsor
- Ethicon Endo-Surgery
Gastrointestinal, Overweight , Obesity
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Impact of CLB101TM️ on Gut Health in Healthy, Overweight Individuals
Anaerostipes caccae CLB101TM️ is a next-generation probiotic isolated from healthy humans. It was shown to be in decreased abundance in people with protein-based food sensitivities/allergies.
- Trial name
- NCT07336615
- Testing
- CLB101™️
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- ClostraBio Inc.
Non-small Cell Lung Cancer, Pancreatic Cancer
Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15
Study to evaluate the efficacy, safety and tolerability of ponsegromab compared to placebo in patients with cancer, cachexia, and elevated GDF 15.
- Conditions
- Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Loss of Appetite
- Trial name
- PROACC-1 (NCT05546476)
- Testing
- ponsegromab
- Where
- 78 sites in United States, Australia and 9 more
- Volunteers
- 187 people
- Sponsor
- Pfizer
Venous Thromboembolism
EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis
The purpose of this study is to evaluate comparative efficacy and safety of rivaroxaban to standard of care in children with acute venous thromboembolism.
- Trial name
- EINSTEIN Jr (NCT02234843)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Standard of Care
- Where
- 109 sites in United States, Argentina and 26 more
- Volunteers
- 500 people
- Sponsor
- Bayer
Weight Loss
VK2735 for Weight Management Phase 2 (Venture Oral Dosing)
This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm dose-finding study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735…
- Trial name
- NCT06828055
- Testing
- VK2735
- Where
- 15 sites in United States
- Volunteers
- 280 people
- Sponsor
- Viking Therapeutics, Inc.
Obesity, Overweight
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additional evidence for the potential clinical benefits of tirzepatide in this population.
- Trial name
- SURMOUNT-MMO (NCT05556512)
- Testing
- Tirzepatide
- Where
- 671 sites in United States, Argentina and 26 more
- Volunteers
- 15,374 people
- Sponsor
- Eli Lilly and Company
Metabolism and Nutrition Disorder, Obesity
Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes
This trial is conducted in Africa, Asia, Europe and the United States of America (USA). The aim of this trial is to investigate the potential of liraglutide to induce and maintain weight loss in overweight or obese subjects with…
- Trial name
- NCT01272232
- Testing
- liraglutide
- Where
- 161 sites in United States, France and 11 more
- Volunteers
- 846 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)
The purpose of this study is to determine the effects of NB relative to placebo on major adverse cardiovascular events (MACE) such as cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in overweight and…
- Trial name
- NCT01601704
- Testing
- NB32, PBO, Weight Management Program
- Where
- 224 sites in United States
- Volunteers
- 8,910 people
- Sponsor
- Orexigen Therapeutics, Inc
Obesity, Mild
Safety & Effectiveness of TENS Weight Management Compared to a Sham
This is a multicenter, randomized, blinded, parallel group, controlled study intended to evaluate the safety and effectiveness of treating overweight and Class 1 obese patients with the Elira System (TENS active treatment)…
- Trial name
- NCT05675384
- Testing
- TENS Active Treatment
- Where
- 6 sites in United States
- Volunteers
- 395 people
- Sponsor
- Elira, Inc.
Text Messaging (Intervention), Control
Text4Diet: A Text Messaging Program for Weight Loss
The purpose of the present RCT is to evaluate a 12-month SMS intervention with expanded content, intervention strategies and interactive database logic, novel online enrollment, and automatic baseline scoring of measures to…
- Trial name
- Text4Diet (NCT01571258)
- Testing
- Text Messaging
- Where
- United States
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Santech, Inc
Diabete Type 2, Obesity
Ph 2a Study of HU6 on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function in Subjects Who Are Overweight or Obese With Type 2 Diabetes
This is a randomized, double-blind, placebo-controlled parallel group study of HU6 and placebo in subjects who are overweight or obese with T2D. The study will be conducted in 4 stages.
- Trial name
- NCT06104358
- Testing
- HU6
- Where
- United States
- Sponsor
- Rivus Pharmaceuticals, Inc.
Chronic Management of Body Weight
Efficacy and Safety of HRS9531 Tablet in Obese Subjects
To evaluate the efficacy of HRS9531 tablet compared with placebo in reducing body weight in obese subjects after 26 weeks of treatment.
- Trial name
- NCT06841445
- Testing
- HRS9531 Tablet
- Where
- China
- Volunteers
- 166 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Obesity, Overweight
A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy
The main purpose of this study is to understand how safe and well-tolerated LY4174794 is in participants with obesity or overweight who are otherwise healthy.
- Trial name
- NCT07654972
- Testing
- LY4174794
- Where
- 3 sites in United States, Singapore
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Obesity
Efficacy of Polyglucosamine Long Term Treatment
The polyglucosamine, specification L112, is a medical device and in this clinical trial used for weight reduction in moderately obese participants following a long term treatment lasting 12 months.
- Trial name
- NCT02682277
- Testing
- polygucosamine
- Where
- Italy
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Certmedica International GmbH
Overweight, Obesity
Effect of GSP3 on Body Weight in Overweight and Obese Subjects
The FLOW (First Loss Of Weight) study is designed to assess the effects of repeated administration of GSP3, an investigational product, on body weight.
- Trial name
- FLOW (NCT03008954)
- Testing
- GSP3, Avicel (modified Cellulose)
- Where
- 5 sites in Czechia, Denmark and 1 more
- Volunteers
- 128 people
- Sponsor
- Gelesis, Inc.
Overweight or Obesity
Multicenter Trial Investigating Performance and Safety of the Medical Device SiPore21®
The present clinical investigation is a randomized, double-blinded, placebo-controlled, multicenter international trial, planned to be conducted in Poland, Romania and Slovakia.
- Trial name
- SHINE (NCT06087822)
- Testing
- IMD SiPore21®
- Where
- 27 sites in Poland, Romania and 1 more
- Volunteers
- 318 people
- Sponsor
- Sigrid Therapeutics AB
Obesity, Metabolic Disease
Xla1 Christensenella Minuta, Phase I, Randomized, Partially Placebo-controlled Double-blind Protocol, Evaluating Safety, Tolerability and Impact on the Gut Microbiota in Healthy Volunteers, Overweight and Obese Adults
Xla1 Christensenella minuta, phase I, randomized, placebo-controlled double-blind protocol, evaluating safety, tolerability and impact on the gut microbiota in healthy volunteers, overweight and obese adults.
- Trial name
- CAUSALITY (NCT04663139)
- Testing
- Xla1
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- YSOPIA Bioscience
Obesity
A Study to Test How Well Different Doses of BI 1356225 Are Tolerated by Men and Women With Obesity or Overweight
The primary objective of this trial is to investigate safety and tolerability of BI 1356225 in male and female patients with overweight and obesity following oral administration of multiple rising doses per day over 28 days.
- Trial name
- NCT04447261
- Testing
- BI 1356225
- Where
- Germany
- Volunteers
- 87 people
- Sponsor
- Boehringer Ingelheim
Overweight, Obesity
Effect of Maridebart Cafraglutide on the Heart's Electrical Activity
The main objective of this trial is to evaluate the effect of maridebart cafraglutide subcutaneously (SC) on the placebo-corrected, change from baseline in QT interval corrected for heart rate using Fridericia's formula in…
- Trial name
- NCT07229157
- Testing
- Maridebart Cafraglutide, Moxifloxacin
- Where
- 2 sites in United States
- Volunteers
- 81 people
- Sponsor
- Amgen
Obese, Overweight
A First in Human Study to Assess the Safety, Tolerability of LB54640 in in Healthy Overweight and Obese Subjects
The aim of this 4-weeks randomized double-blind placebo-controlled single and multiple ascending dose study is to assess the Safety and Tolerability of LB54640 in Healthy overweight and obese subjects
- Conditions
- Obese, Overweight, Healthy
- Trial name
- NCT06040372
- Testing
- LB64640
- Where
- United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- LG Chem